Loading

Renal Cell Carcinoma

CLEAR: Lenvatinib, Pembrolizumab Showed Continued Benefit in Advanced RCC

Combination treatment with first-line lenvatinib plus pembrolizumab continued to show a clinically meaningful benefit at 2 years compared with sunitinib in patients with advanced renal cell carcinoma (RCC). These updated results of the CLEAR study were presented by Camillo G. Porta, of University of Bari, Italy, at the ESMO Congress 2022. ...

Advertisement

Latest News

Advertisement

Knowledge Hub Spotlights

Curated clinical content based on conditions, therapies, and technologies

Phenotypic Precision Medicine in Advanced Prostate Cancer
Phenotypic Precision Medicine in Advanced Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Trending

Emily Menendez

RLT-PSMA | August 18, 2022

The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.

Emily Menendez

RLT-PSMA | August 18, 2022

Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.

Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.